NEXT Financial Group Inc bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 759 shares of the company’s stock, valued at approximately $209,000.
Several other institutional investors have also recently modified their holdings of the company. Fundsmith LLP grew its holdings in shares of IDEXX Laboratories by 0.8% in the first quarter. Fundsmith LLP now owns 4,467,341 shares of the company’s stock worth $998,897,000 after purchasing an additional 35,049 shares during the last quarter. Blair William & Co. IL raised its position in shares of IDEXX Laboratories by 0.7% in the 1st quarter. Blair William & Co. IL now owns 1,582,222 shares of the company’s stock worth $353,785,000 after purchasing an additional 10,586 shares during the last quarter. American Century Companies Inc. raised its position in shares of IDEXX Laboratories by 111.2% in the 1st quarter. American Century Companies Inc. now owns 1,483,074 shares of the company’s stock worth $331,615,000 after purchasing an additional 780,846 shares during the last quarter. Geode Capital Management LLC raised its position in shares of IDEXX Laboratories by 7.6% in the 4th quarter. Geode Capital Management LLC now owns 1,162,909 shares of the company’s stock worth $215,959,000 after purchasing an additional 81,641 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in IDEXX Laboratories by 36.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,076,895 shares of the company’s stock worth $240,793,000 after buying an additional 289,063 shares in the last quarter. Hedge funds and other institutional investors own 88.05% of the company’s stock.
In other news, VP Michael Lane sold 1,812 shares of IDEXX Laboratories stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $245.41, for a total transaction of $444,682.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Rebecca M. Henderson sold 8,790 shares of IDEXX Laboratories stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $241.57, for a total value of $2,123,400.30. Following the transaction, the director now directly owns 27,486 shares in the company, valued at $6,639,793.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,202 shares of company stock worth $3,218,447. Insiders own 2.70% of the company’s stock.
Shares of IDEXX Laboratories stock traded down $4.93 during trading hours on Monday, reaching $263.78. 4,491 shares of the stock traded hands, compared to its average volume of 363,310. The business’s 50 day moving average is $278.78. The company has a market capitalization of $23.12 billion, a price-to-earnings ratio of 61.90 and a beta of 0.84. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $292.17. The company has a quick ratio of 0.74, a current ratio of 1.15 and a debt-to-equity ratio of 4.08.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a return on equity of 765.45% and a net margin of 17.78%. The firm had revenue of $620.10 million for the quarter, compared to analysts’ expectations of $627.10 million. During the same period in the previous year, the firm earned $1.23 EPS. The business’s quarterly revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 4.9 EPS for the current year.
Several equities research analysts recently commented on the company. Canaccord Genuity reiterated a “buy” rating and issued a $285.00 price objective on shares of IDEXX Laboratories in a report on Friday. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price target for the company in a research note on Friday, May 3rd. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 26th. Guggenheim started coverage on IDEXX Laboratories in a research note on Thursday, May 23rd. They set a “buy” rating and a $276.00 price target for the company. Finally, Bank of America set a $300.00 price target on IDEXX Laboratories and gave the company a “buy” rating in a research note on Friday, June 21st. Seven equities research analysts have rated the stock with a buy rating, IDEXX Laboratories currently has an average rating of “Buy” and an average price target of $281.00.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Story: Moving Average (MA)
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.